Plasma pentraxin 3 levels do not predict coronary events but reflect metabolic disorders in patients with coronary artery disease in the CARE trial

PLoS ONE

Volumn 9, Issue 4, 2014, Pages

  Miyazaki, Tetsuro ^a   Chiuve, Stephanie ^b   Sacks, Frank M ^a,b   Ridker, Paul M ^a   Libby, Peter ^a   Aikawa, Masanori ^a  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

^b HARVARD SCHOOL OF PUBLIC HEALTH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; AMYLOID A PROTEIN; ANTIARRHYTHMIC AGENT; ANTICOAGULANT AGENT; ANTILIPEMIC AGENT; APOLIPOPROTEIN C3; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; C REACTIVE PROTEIN; CALCIUM CHANNEL BLOCKING AGENT; CHOLESTEROL; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LOW DENSITY LIPOPROTEIN CHOLESTEROL; PENTRAXIN 3; PLACEBO; PRAVASTATIN; TISSUE PLASMINOGEN ACTIVATOR; TRIACYLGLYCEROL; BIOLOGICAL MARKER; SERUM AMYLOID P;

ADULT; ARTICLE; BODY MASS; CASE CONTROL STUDY; CHOLESTEROL BLOOD LEVEL; CONTROLLED STUDY; CORONARY ARTERY DISEASE; CORRELATION ANALYSIS; DISEASE ASSOCIATION; DOUBLE BLIND PROCEDURE; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; FOLLOW UP; HEART DEATH; HEART INFARCTION; HUMAN; MAJOR CLINICAL STUDY; MALE; METABOLIC DISORDER; PROSPECTIVE STUDY; PROTEIN ANALYSIS; PROTEIN BLOOD LEVEL; PROTEIN FUNCTION; RANDOMIZED CONTROLLED TRIAL; RECURRENT DISEASE; TRIACYLGLYCEROL BLOOD LEVEL; WAIST CIRCUMFERENCE; AGED; BLOOD; CLINICAL TRIAL; METABOLIC SYNDROME X; METABOLISM; MIDDLE AGED; OBESITY; PROGNOSIS; RISK; RISK FACTOR;

ADULT; AGED; BIOLOGICAL MARKERS; C-REACTIVE PROTEIN; CORONARY ARTERY DISEASE; FEMALE; HUMANS; MALE; METABOLIC SYNDROME X; MIDDLE AGED; OBESITY; ODDS RATIO; PROGNOSIS; RISK FACTORS; SERUM AMYLOID P-COMPONENT;

EID: 84899055940     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0094073     Document Type: Article

References (42)

1. Garlanda C, Bottazzi B, Bastone A, Mantovani A (2005) Pentraxins at the crossroads between innate immunity, inflammation, matrix deposition, and female fertility. Annu Rev Immunol 23: 337-366. (Pubitemid 40563173)
2. Bottazzi B, Garlanda C, Cotena A, Moalli F, Jaillon S, et al. (2009) The long pentraxin PTX3 as a prototypic humoral pattern recognition receptor: interplay with cellular innate immunity. Immunol Rev 227: 9-18.
3. Pepys MB, Hirschfield GM (2003) C-reactive protein: a critical update. J Clin Invest 111: 1805-1812. (Pubitemid 38057722)
4. Ridker PM, Hennekens CH, Buring JE, Rifai N (2000) C-reactive protein and other markers of inflammation in the prediction of cardiovascular disease in women. N Engl J Med 342: 836-843. (Pubitemid 30165206)
5. Inoue K, Sugiyama A, Reid PC, Ito Y, Miyauchi K, et al. (2007) Establishment of a high sensitivity plasma assay for human pentraxin3 as a marker for unstable angina pectoris. Arterioscler Thromb Vasc Biol 27: 161-167. (Pubitemid 46360394)
6. Peri G, Introna M, Corradi D, Iacuitti G, Signorini S, et al. (2000) PTX3, A prototypical long pentraxin, is an early indicator of acute myocardial infarction in humans. Circulation 102: 636-641. (Pubitemid 30640663)
7. Latini R, Maggioni AP, Peri G, Gonzini L, Lucci D, et al. (2004) Prognostic significance of the long pentraxin PTX3 in acute myocardial infarction. Circulation 110: 2349-2354. (Pubitemid 39407338)
8. Suzuki S, Takeishi Y, Niizeki T, Koyama Y, Kitahara T, et al. (2008) Pentraxin 3, a new marker for vascular inflammation, predicts adverse clinical outcomes in patients with heart failure. Am Heart J 155: 75-81. (Pubitemid 350234768)
9. Camozzi M, Zacchigna S, Rusnati M, Coltrini D, Ramirez-Correa G, et al. (2005) Pentraxin 3 inhibits fibroblast growth factor 2-dependent activation of smooth muscle cells in vitro and neointima formation in vivo. Arterioscler Thromb Vasc Biol 25: 1837-1842. (Pubitemid 41243451)
10. Salio M, Chimenti S, De Angelis N, Molla F, Maina V, et al. (2008) Cardioprotective function of the long pentraxin PTX3 in acute myocardial infarction. Circulation 117: 1055-1064.
11. Jenny NS, Arnold AM, Kuller LH, Tracy RP, Psaty BM (2009) Associations of pentraxin 3 with cardiovascular disease and all-cause death: the cardiovascular health study. Arterioscler Thromb Vasc Biol 29: 594-599.
12. Norata GD, Marchesi P, Pulakazhi Venu VK, Pasqualini F, Anselmo A, et al. (2009) Deficiency of the long pentraxin PTX3 promotes vascular inflammation and atherosclerosis. Circulation 120: 699-708.
13. Deban L, Russo RC, Sironi M, Moalli F, Scanziani M, et al. (2010) Regulation of leukocyte recruitment by the long pentraxin PTX3. Nature immunology 11: 328-334.
14. Matsubara J, Sugiyama S, Nozaki T, Sugamura K, Konishi M, et al. (2011) Pentraxin 3 is a new inflammatory marker correlated with left ventricular diastolic dysfunction and heart failure with normal ejection fraction. J Am Coll Cardiol 57: 861-869.
15. Miyamoto T, Rashid Qureshi A, Heimburger O, Barany P, Carrero K, et al. (2011) Inverse relationship between the inflammatory marker pentraxin-3, fat body mass, and abdominal obesity in end-stage renal disease. Clin J Am Soc Nephrol 6: 2785-2791.
16. Dubin R, Li Y, Ix JH, Shlipak MG, Whooley M, et al. (2012) Associations of pentraxin-3 with cardiovascular events, incident heart failure, and mortality among persons with coronary heart disease: Data from the Heart and Soul Study. Am Heart J 163: 274-279.
17. Suzuki S, Shishido T, Funayama A, Netsu S, Ishino M, et al. (2013) Long pentraxin PTX3 exacerbates pressure overload-induced left ventricular dysfunction. PLoS One 8: e53133.
18. Maekawa Y, Nagai T, Anzai A (2011) Pentraxins: CRP and PTX3 and cardiovascular disease. Inflamm Allergy Drug Targets 10: 229-235.
19. Inoue K, Kodama T, Daida H (2012) Pentraxin 3: a novel biomarker for inflammatory cardiovascular disease. Int J Vasc Med 2012: 657025.
20. Yamasaki K, Kurimura M, Kasai T, Sagara M, Kodama T, et al. (2009) Determination of physiological plasma pentraxin 3 (PTX3) levels in healthy populations. Clin Chem Lab Med 47: 471-477.
21. Sacks FM, Pfeffer MA, Moye LA, Rouleau JL, Rutherford JD, et al. (1996) The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and Recurrent Events Trial investigators. N Engl J Med 335: 1001-1009. (Pubitemid 26338729)
22. Pfeffer MA, Sacks FM, Moye LA, Brown L, Rouleau JL, et al. (1995) Cholesterol and Recurrent Events: a secondary prevention trial for normolipidemic patients. CARE Investigators. Am J Cardiol 76: 98C-106C.
23. Ridker PM, Rifai N, Pfeffer MA, Sacks F, Braunwald E (1999) Long-term effects of pravastatin on plasma concentration of C-reactive protein. The Cholesterol and Recurrent Events (CARE) Investigators. Circulation 100: 230-235. (Pubitemid 29340127)
24. Grundy SM, Cleeman JI, Daniels SR, Donato KA, Eckel RH, et al. (2005) Diagnosis and management of the metabolic syndrome: an American Heart Association/National Heart, Lung, and Blood Institute Scientific Statement. Circulation 112: 2735-2752. (Pubitemid 41532612)
25. Rolph MS, Zimmer S, Bottazzi B, Garlanda C, Mantovani A, et al. (2002) Production of the long pentraxin PTX3 in advanced atherosclerotic plaques. Arterioscler Thromb Vasc Biol 22: e10-14.
26. Savchenko A, Imamura M, Ohashi R, Jiang S, Kawasaki T, et al. (2008) Expression of pentraxin 3 (PTX3) in human atherosclerotic lesions. J Pathol 215: 48-55. (Pubitemid 351619875)
27. Alles VV, Bottazzi B, Peri G, Golay J, Introna M, et al. (1994) Inducible expression of PTX3, a new member of the pentraxin family, in human mononuclear phagocytes. Blood 84: 3483-3493. (Pubitemid 24352913)
28. Souza DG, Soares AC, Pinho V, Torloni H, Reis LF, et al. (2002) Increased mortality and inflammation in tumor necrosis factor-stimulated gene-14 transgenic mice after ischemia and reperfusion injury. Am J Pathol 160: 1755-1765. (Pubitemid 34525655)
29. Breviario F, d'Aniello EM, Golay J, Peri G, Bottazzi B, et al. (1992) Interleukin-1-inducible genes in endothelial cells. Cloning of a new gene related to Creactive protein and serum amyloid P component. J Biol Chem 267: 22190-22197.
30. Klouche M, Peri G, Knabbe C, Eckstein HH, Schmid FX, et al. (2004) Modified atherogenic lipoproteins induce expression of pentraxin-3 by human vascular smooth muscle cells. Atherosclerosis 175: 221-228. (Pubitemid 38942901)
31. Doni A, Michela M, Bottazzi B, Peri G, Valentino S, et al. (2006) Regulation of PTX3, a key component of humoral innate immunity in human dendritic cells: stimulation by IL-10 and inhibition by IFN-gamma. J Leukoc Biol 79: 797-802. (Pubitemid 44835611)
32. Norata GD, Marchesi P, Pirillo A, Uboldi P, Chiesa G, et al. (2008) Long pentraxin 3, a key component of innate immunity, is modulated by high-density lipoproteins in endothelial cells. Arterioscler Thromb Vasc Biol 28: 925-931. (Pubitemid 351544109)
33. Matter CM, Handschin C (2007) RANTES (regulated on activation, normal T cell expressed and secreted), inflammation, obesity, and the metabolic syndrome. Circulation 115: 946-948. (Pubitemid 46328286)
34. Shah PK (2007) Innate immune pathway links obesity to insulin resistance. Circ Res 100: 1531-1533.
35. Hajer GR, van Haeften TW, Visseren FL (2008) Adipose tissue dysfunction in obesity, diabetes, and vascular diseases. European heart journal 29: 2959-2971.
36. Ridker PM, Buring JE, Cook NR, Rifai N (2003) C-reactive protein, the metabolic syndrome, and risk of incident cardiovascular events: an 8-year followup of 14 719 initially healthy American women. Circulation 107: 391-397.
37. Alberti L, Gilardini L, Zulian A, Micheletto G, Peri G, et al. (2009) Expression of long pentraxin PTX3 in human adipose tissue and its relation with cardiovascular risk factors. Atherosclerosis 202: 455-460.
38. Abderrahim-Ferkoune A, Bezy O, Chiellini C, Maffei M, Grimaldi P, et al. (2003) Characterization of the long pentraxin PTX3 as a TNFalpha-induced secreted protein of adipose cells. J Lipid Res 44: 994-1000. (Pubitemid 37279659)
39. Fung E, Tang SM, Canner JP, Morishige K, Arboleda-Velasquez JF, et al. (2007) Delta-like 4 induces notch signaling in macrophages: implications for inflammation. Circulation 115: 2948-2956. (Pubitemid 46912098)
40. Zheng C, Khoo C, Ikewaki K, Sacks FM (2007) Rapid turnover of apolipoprotein C-III-containing triglyceride-rich lipoproteins contributing to the formation of LDL subfractions. J Lipid Res 48: 1190-1203. (Pubitemid 46708686)
41. Zheng C, Azcutia V, Aikawa E, Figueiredo JL, Croce K, et al. (2013) Statins suppress apolipoprotein CIII-induced vascular endothelial cell activation and monocyte adhesion. European heart journal 34: 615-624.
42. Suliman ME, Yilmaz MI, Carrero JJ, Qureshi AR, Saglam M, et al. (2008) Novel links between the long pentraxin 3, endothelial dysfunction, and albuminuria in early and advanced chronic kidney disease. Clin J Am Soc Nephrol 3: 976-985.